A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

Protocol No
AZ-D933QC00001-ADRIATIC
Principal Investigator
Jonathan Thompson
Phase
III
Summary
This project is being done to find out if the medication called Durvalumab and Tremelimumab will work and be safe for the treatment of Limited Stage Small-Cell Lung Cancer (LS-SCLC).
Description
Durvalumab or Durvalumab and Tremelimumab for Patients with Stage I-III LLimited Disease SCLC
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: